Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0265264 (
HOS
)
1,119
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
WW domain-containing oxidoreductase
(
WWOX
) is a tumor suppressor that is deleted or attenuated in most human tumors. Wwox-deficient mice develop osteosarcoma (OS), an aggressive bone tumor with poor prognosis that often metastasizes to lung. On the basis of these observations, we examined the status of
WWOX
in human OS specimens and cell lines. In human OS clinical samples,
WWOX
expression was absent or reduced in 58% of tumors examined (P < 0.0001). Compared with the primary tumors,
WWOX
levels frequently increased in tumors resected following chemotherapy. In contrast, tumor metastases to lung often exhibited reduced
WWOX
levels relative to the primary tumor. In human OS cell lines having reduced
WWOX
expression, ectopic expression of
WWOX
inhibited proliferation and attenuated invasion in vitro, and suppressed tumorigenicity in nude mice. Expression of
WWOX
was associated with reduced RUNX2 expression in OS cell lines, whereas RUNX2 levels were elevated in femurs of Wwox-deficient mice. Furthermore,
WWOX
reconstitution in
HOS
cells was associated with downregulation of RUNX2 levels and RUNX2 target genes, consistent with the ability of
WWOX
to suppress RUNX2 transactivation activity. In clinical samples, RUNX2 was expressed in the majority of primary tumors and undetectable in most tumors resected following chemotherapy, whereas most metastases were RUNX2 positive. Our results deepen the evidence of a tumor suppressor role for
WWOX
in OS, furthering its prognostic and therapeutic significance in this disease.
...
PMID:Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. 2053 Jun 75
Osteosarcoma (OS) is among the most frequently occurring primary bone tumors, primarily affecting adolescents and young adults. This malignant osteoid forming tumor is characterized by its metastatic potential, mainly to lungs. We recently demonstrated that
WW domain-containing oxidoreductase
(
WWOX
) is frequently inactivated in human OS and that
WWOX
restoration in
WWOX
-negative OS cells suppresses tumorigenicity. Of note,
WWOX
levels are reduced in paired OS samples of post-treatment metastastectomies as compared to pre-treatment biopsies suggesting that decreased
WWOX
levels are associated with a more aggressive phenotype at the metastatic site. Nevertheless, little is known about
WWOX
function in OS metastasis. Here, we investigated the role of tumor suppressor
WWOX
in suppressing pulmonary OS metastasis both in vitro and in vivo. We demonstrated that ectopic expression of
WWOX
in OS cells,
HOS
and LM-7, inhibits OS invasion and cell migration in vitro. Furthermore,
WWOX
expression reduced tumor burden in vivo and inhibited metastases' seeding and colonization. Mechanistically,
WWOX
function is associated with reduced levels of RUNX2 metastatic target genes implicated in adhesion and motility. Our results suggest that
WWOX
plays a critical role in determining the aggressive phenotype of OS, and its expression could be an attractive therapeutic target to combat this devastating adolescent disease.
...
PMID:Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. 2625 46